Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Abstract

PurposeTo evaluate the safety of two commercially available formulations of bimatoprost eye drops: 0.03 and 0.01% ophthalmic solutions.MethodsThis was a randomized, prospective, parallel-group, open-label, cohort study. A total of 60 glaucoma patients (60 eyes) under bimatoprost 0.03% monotherapy since at least 1 year were enrolled. Selected patients were… (More)
DOI: 10.1038/eye.2013.304

Topics

5 Figures and Tables

Cite this paper

@article{Figus2014Bimatoprost0V, title={Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients}, author={Michele Figus and Marco Nardi and Paolo Piaggi and Maria Sole Sartini and Giorgio Guidi and Lorena Martini and Stefano Lazzeri}, journal={Eye}, year={2014}, volume={28}, pages={422-429} }